[go: up one dir, main page]

ATE161720T1 - Tnf-inhibitoren - Google Patents

Tnf-inhibitoren

Info

Publication number
ATE161720T1
ATE161720T1 AT91913854T AT91913854T ATE161720T1 AT E161720 T1 ATE161720 T1 AT E161720T1 AT 91913854 T AT91913854 T AT 91913854T AT 91913854 T AT91913854 T AT 91913854T AT E161720 T1 ATE161720 T1 AT E161720T1
Authority
AT
Austria
Prior art keywords
tnf inhibitors
tnf
inhibitors
Prior art date
Application number
AT91913854T
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen
Klaus Max Esser
Philip Leonard Simon
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE161720T1 publication Critical patent/ATE161720T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT91913854T 1990-08-03 1991-07-29 Tnf-inhibitoren ATE161720T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56276190A 1990-08-03 1990-08-03

Publications (1)

Publication Number Publication Date
ATE161720T1 true ATE161720T1 (de) 1998-01-15

Family

ID=24247660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91913854T ATE161720T1 (de) 1990-08-03 1991-07-29 Tnf-inhibitoren

Country Status (13)

Country Link
US (1) US5420154A (de)
EP (1) EP0542795B1 (de)
JP (1) JPH06500078A (de)
AP (1) AP9100310A0 (de)
AT (1) ATE161720T1 (de)
AU (1) AU8292091A (de)
CA (1) CA2088352A1 (de)
DE (1) DE69128627T2 (de)
DK (1) DK0542795T5 (de)
IE (1) IE912730A1 (de)
IL (1) IL99024A0 (de)
MX (1) MX9100494A (de)
WO (1) WO1992002220A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996020157A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-ol dimers and related compounds
IL117090A (en) * 1995-02-10 2000-07-26 Schering Ag Pharmaceutical compositions containing oxazolidinone derivatives
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
EP2223920A3 (de) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituierte Azabizyklische Verbindungen
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
KR19980074060A (ko) * 1997-03-21 1998-11-05 김윤배 신규한 치환된 3,4-디알콕시페닐 유도체
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002081447A1 (en) * 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
WO2002081446A1 (en) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
US7652025B2 (en) * 2001-05-08 2010-01-26 Toray Industries, Inc. Remedies for sepsis
EP1409016B9 (de) 2001-06-26 2020-10-28 Amgen Fremont Inc. Antikörper gegen opgl
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
CN100562342C (zh) 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
US20090036528A1 (en) * 2007-07-31 2009-02-05 Hugli Tony E Multifunctional and combinational application of aspartame and or futhan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923833A (en) * 1968-05-01 1975-12-02 Hoffmann La Roche N-{8 (1-cyano-2-phenyl)ethyl{9 carbamates
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DE2655369A1 (de) * 1976-12-03 1978-06-08 Schering Ag 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
FI875724A7 (fi) * 1986-04-29 1987-12-28 Pfizer Kalsiumista riippumaton cAMP fosfodiesteraasi-inhibiittori-masennukse nvastainen lääke.
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
CA2058952A1 (en) * 1989-06-13 1990-12-14 Nabil Hanna Monokine activity interference
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬

Also Published As

Publication number Publication date
JPH06500078A (ja) 1994-01-06
DE69128627T2 (de) 1998-07-02
IL99024A0 (en) 1992-07-15
AP9100310A0 (en) 1993-02-01
DK0542795T5 (da) 1998-09-07
DE69128627D1 (de) 1998-02-12
AU8292091A (en) 1992-03-02
WO1992002220A1 (en) 1992-02-20
EP0542795B1 (de) 1998-01-07
CA2088352A1 (en) 1992-02-04
IE912730A1 (en) 1992-02-12
US5420154A (en) 1995-05-30
DK0542795T3 (da) 1998-03-16
EP0542795A1 (de) 1993-05-26
MX9100494A (es) 1992-04-01

Similar Documents

Publication Publication Date Title
DE69128627D1 (de) Tnf-inhibitoren
FI933303L (fi) Adenosinkinasinhibitorer
DE69227227D1 (de) Korrosionsinhibitoren
FI930090L (fi) Spaerrverk foer fall
FI960803A0 (fi) TNF-alfa-sekreetion inhibiittoreita
FI931488L (fi) Tnf-muteiner
FI921435L (fi) Skydd foer saenkpump i svaora foerhaollanden
BR8907457A (pt) Inibidores de interleucina-1
FI922759L (fi) Loesningsmedelskompositioner foer anvaendning i tryckkaensligt kopieringspapper
FI923724A7 (fi) Monterings- och distansanordning foer braenslestavarna i en kokvattenreaktor
FI921191L (fi) Tryckluftsfoersoerjningsanordning foer tryckluftsanlaeggningar i fordon
FI924750A0 (fi) Zirkoniumbaserad legering foer komponenter i kaernreaktorer
AP9100335A0 (en) Tnf inhibitors
NO923339D0 (no) Korrosjonsinhibitor
FI922180L (fi) Tuggummi innehaollande tuggummibas i en valsningsblandning
FI101796B1 (fi) Uusia -glukosidaasi-inhibiittoreita
FI922681L (fi) Nytt foerpacknings/behaollarsystem
FI934447L (fi) Nytt immunhaemmande aemne fraon strptomyces braegensis
FI915200L (fi) Foerfarande foer olineaer signalbehandling i en ekoslaeckare
FI922173L (fi) Externt justerbar styranordning foer stroemningsbegraensgning i tallriksventiler
DE69214142D1 (de) Lotnivellierer
FI922683L (fi) Nytt foerpacknings/behaollarsystem
FI920998L (fi) Skaermad hytt i modulkonstruktion
FI915232A7 (fi) Esteri-inhibiittorit
DE69120024D1 (de) Neovascularisationsinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties